PURASORB PLC 9538 is a medical-device-grade poly(L-lactide-co-ε-caprolactone) supplied as white to off-white granules. The copolymer is manufactured by ring-opening polymerisation of L-lactide and ε-caprolactone under current good manufacturing practice; the nominal L-lactide to ε-caprolactone molar ratio is 95:5 and the product code defines an inherent viscosity midpoint of 3.8 dL/g when measured in chloroform at 25 °C and a concentration of 0.1 g/dL. This follows the PURASORB naming convention in which PLC 7015 designates a 70:30 lactide-caprolactone copolymer with a lower viscosity midpoint and PLC 8516 designates an 85:15 intermediate composition. Inherent viscosity is determined by Ubbelohde capillary viscometry according to ISO 1628-1:2021.

Certificates of analysis for each batch report inherent viscosity, residual lactide and ε-caprolactone monomers, residual tin, heavy metals, loss on drying, and bioburden. Residual monomers in this product class are commonly controlled below 0.5 wt%; residual tin from the stannous octoate catalyst is commonly below 10 ppm. The user should verify acceptance limits against the batch certificate because compendial or device-specific requirements may be tighter. The polymer is semi-crystalline, with a glass transition typically in the 55–60 °C range and a melting endotherm typically in the 170–180 °C range at 10 °C/min under nitrogen when analysed according to ISO 11357-3:2018; exact thermal transitions are thermal-history dependent and are not manufacturer specification values.

The copolymer is intended for long-term resorbable medical devices, including interference screws, suture anchors, meniscal repair implants, rib fixation devices, and drug-eluting implant matrices. It is not intended for permanent load-bearing implants or for applications requiring elastomeric recovery; the 70:30 PLC grade is more appropriate where higher elongation and softer tissue compliance are required. PLC 9538 provides a balance of processability in conventional melt-processing equipment and retention of mechanical integrity during the early stages of hydrolysis. In comparison with poly(L-lactide) homopolymer, the 5 mol% ε-caprolactone co-unit interrupts the L-lactide sequence and reduces the tendency toward quench-induced cracking during injection molding and film orientation.

What does the 5 mol% ε-caprolactone sequence change in semi-crystalline resorbable polyester performance?

The 5 mol% ε-caprolactone co-unit disrupts the stereoregular L-lactide sequences and reduces the crystallisation rate relative to PLLA homopolymer. The result is a semi-crystalline matrix with a lower glass transition temperature and a lower tensile modulus than high-IV PLLA homopolymers such as PURASORB PL 38. Because caprolactone repeat units are largely excluded from the ordered crystalline lattice, they concentrate in the amorphous inter-lamellar regions and modify the yield and fracture behaviour of injection-molded devices. In tensile tests following ISO 527-2:2012 or ASTM D638-14, finished devices must be tested directly because molecular orientation, annealing, and crystalline content control the measured values; published data for this specific product configuration is limited and should not be substituted by PLLA homopolymer data.

From a resorption standpoint, the lower caprolactone content maintains a longer strength-retention profile than PLC 7015 under identical in vitro conditions. Hydrolytic degradation is the dominant mechanism, and the initial rate is governed by water diffusion into the amorphous phase, ester-linkage concentration, and local pH autocatalysis. The 95:5 grade shows slower mass loss than amorphous PLGA copolymers containing glycolic acid because the degradation products are lactic acid and 6-hydroxycaproic acid, with a smaller initial acidic burst. Comparative ranking should be confirmed by ASTM F1635-16 in vitro degradation testing at 37 °C in phosphate-buffered saline at pH 7.4.

After moisture has been removed to a verified level below 0.02 wt%, PLC 9538 can be processed on standard single-screw and twin-screw equipment. A desiccant dryer with a dew point below −40 °C or a vacuum dryer at 80 °C for 8–12 h is suitable for incoming granules. Because the ester backbone is hydrolytically sensitive, any lapse in drying control before extrusion or injection molding produces molecular weight loss, a lower melt viscosity, and bubbles in the final part. Batch-to-batch variation in inherent viscosity within the specification window changes the melt-pressure profile; therefore, the screw speed and barrel profile must be adjusted using melt-pressure and motor-load data rather than fixed set points.

For injection molding, clamp forces between 25 t and 100 t are common for small-to-medium orthopedic fasteners and anchors. Barrel temperatures should follow a rising profile from 170 °C at the feed throat to 195–205 °C at the nozzle, with mold temperatures between 25 °C and 60 °C depending on the required crystallinity. Low mold temperatures produce a more amorphous, transparent part with lower modulus; higher mold temperatures or post-mold annealing at 100–120 °C increase crystallinity and dimensional stability. In production, a mold temperature above 60 °C can extend cycle time and produce sticking if the part is under-crystallized; ejector design and draft angles must account for this.

Tubing, monofilament, and film extrusion are performed on single-screw extruders with L/D ratios from 24:1 to 30:1 and barrel temperatures from 180 °C to 200 °C. Uniaxial drawing at 90–110 °C with draw ratios from 2:1 to 4:1 induces orientation and increases tensile strength along the draw axis. Drawing below the glass transition causes voiding and fibrillation; drawing above the optimum range relaxes orientation and reduces strength. Published data for this specific product configuration is limited; the stated ranges are consistent with semi-crystalline lactide-rich copolymer processing and should be verified on the production line.

When the implant must outlast a 70:30 PLC device, the 95:5 grade changes the design envelope

When the implant must retain load-bearing function beyond the resorption window of PLC 7015, the 95:5 composition offers a longer strength-retention period because the higher L-lactide fraction supports a higher initial modulus and a more persistent semi-crystalline network. In phosphate-buffered saline at 37 °C and pH 7.4, mass loss for 95:5 lactide-caprolactone copolymer implants is reported in peer-reviewed literature to occur over a longer timescale than for 70:30 PLC; however, published data for this specific product configuration is limited, and specimen porosity, annealing history, and molecular weight at the start of testing dominate the measured results. Real-time degradation studies should follow ASTM F1635-16 and the device-specific sampling plan.

Compared with PLLA homopolymer, PLC 9538 shows a reduction in brittleness and a smaller tendency to craze under load, which is useful for devices that undergo bending during insertion. Compared with PLGA 85:15, PLC 9538 does not release glycolic acid and therefore shows a less aggressive local pH drop; this can be an advantage at bony or neural interfaces where acidic degradation products are a clinical concern. The material is not, however, a replacement for polycaprolactone homopolymer where high flexibility and very slow resorption are required. Selection among PLC 9538, PLC 8516, and PLC 7015 is therefore based on the required mechanical modulus, strain at break, and the intended resorption timeline in the target tissue.

Under simulated in vivo conditions, hydrolytic degradation of PLC 9538 proceeds first in the amorphous regions, where water diffusion is highest and the glass transition is most easily plasticised. Molecular weight decreases before mass loss begins; therefore, mechanical strength may decline before visible dimensional change occurs. The onset of autocatalytic hydrolysis inside thick implants can create a pH gradient between surface and core, leading to faster core degradation and the release of soluble oligomers. This phenomenon is geometry-dependent and must be evaluated by sectioning devices at terminal time points in a real-time in vitro model.

Process-related degradation is distinct from in vivo degradation. During melt processing, residual moisture, excessive barrel temperature, and long residence time hydrolyse the ester backbone and shift the molecular weight distribution toward lower values. The resulting melt may process acceptably but the finished part will have lost fracture resistance. Production-scale extruders with closed-loop vacuum drying and melt-temperature monitoring provide better lot-to-lot consistency than lab-scale batches. Recorded variables should include melt pressure, melt temperature at the die, screw speed, and barrel set points to trace off-specification mechanical results.

Regulatory compliance matrix for long-term implantable devices using PLC 9538

Regulatory compliance for a PLC 9538-based device is established at the finished-device level. The supplier certificate of analysis supports material traceability under ISO 13485:2016, but the device manufacturer remains responsible for biocompatibility, sterilization, and packaging validation. The table below lists the standards most commonly cited in technical documentation for long-term resorbable lactide-caprolactone copolymer implants.

Chemical characterisation under ISO 10993-18:2020 should include oligomeric and degradation-product profiling because low-molecular-mass fractions can migrate from the implant surface during initial contact with tissue. Residual solvent from solvent-casting operations, if used, must also be quantified and controlled by gas chromatography with headspace sampling. The endpoint for biocompatibility is not determined solely by the raw polymer; processing aids, mold release, packaging materials, and sterilization residues contribute to the extractable profile and must be included in the toxicological risk assessment.

Sterilization validation for devices made from PLC 9538 is performed with ethylene oxide according to ISO 11135:2014 or with gamma radiation according to ISO 11137-1. Gamma irradiation at doses up to 25 kGy can reduce molecular weight; therefore, the highest delivered dose in routine production must be used to establish the post-sterilization mechanical margin. Ethylene oxide residuals must be controlled according to ISO 10993-7:2008. Steam sterilization is not recommended because the combination of moisture and heat above the glass transition accelerates hydrolysis and can induce dimensional change.

Shelf-life and packaging validation follow ISO 11607-1:2019 and ISO 11607-2:2019. The polymer is sensitive to moisture and should be stored in sealed, dry, cool conditions; the original aluminum-laminated pouch should remain closed until use. If the pouch is opened and the material is not consumed, the remaining granules must be re-dried below 0.02 wt% before processing. PLC 9538 is not compatible with alkaline solutions, amine-based additives, or residual strong acids, which accelerate ester hydrolysis. Filler selection for composite devices should include a pre-screening of surface pH because basic calcium phosphates and silicates can alter the local degradation microenvironment.